STYXL2: A Potential Drug Target and Biomarker (G92235)

Target Name: STYXL2

NCBI ID: G92235

STYXL2

STYXL2: A Potential Drug Target and Biomarker

Introduction

Styxl2 is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the microtubule network, which is a complex of filaments that transports proteins within cells. The microtubule network plays a crucial role in cell division, intracellular transport, and other cellular processes. STYXL2 is highly conserved across various species, which suggests that it may be a universal regulator of microtubule dynamics.

Recent studies have identified STYXL2 as a potential drug target and biomarker. This is because of its central role in regulating microtubule dynamics and its potential to modulate the functions of various cellular processes. In this article, we will discuss the recent findings on STYXL2, its potential drug target status, and its potential as a biomarker.

Potential Drug Target

STYXL2 has been identified as a potential drug target due to its involvement in various cellular processes. The microtubule network is a complex of filaments that transports proteins within cells. The filaments are made up of a protein called tubulin, which is a key component of the microtubules. STYXL2 is highly conserved across various species and has been shown to regulate the assembly and disassembly of tubulin filaments.

This suggests that STYXL2 may be a useful target for drugs that target the microtubule network. One potential drug that may target STYXL2 is the drug BAY 94-9342, which is a inhibitor of the protein kinase CKL2. CKL2 is a non-receptor tyrosine kinase that is involved in various cellular processes, including cell division, DNA replication, and protein synthesis.

Inhibition of CKL2 has been shown to be a powerful treatment for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By targeting STYXL2, the drug BAY 94-9342 may be able to modulate the microtubule network and disrupt the functions of various cellular processes.

Biomarker

In addition to its potential as a drug target, STYXL2 has also been identified as a potential biomarker. The microtubule network is a complex of filaments that is highly sensitive to disruptions, such as those that occur due to disease or aging. This suggests that changes in the microtubule network may be a useful indicator of disease or aging.

Studies have shown that various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, are associated with changes in the microtubule network. For example, altered microtubule dynamics have been observed in various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Similarly, changes in microtubule dynamics have also been observed in cancer, where increased microtubule density has been observed in various types of cancer.

In addition to its association with disease, STYXL2 has also been shown to be a potential biomarker for some diseases. For example, altered microtubule dynamics have been observed in individuals with Inflammatory Neuropathway-related diseases (INNDs), which are characterized by inflammation and neurodegeneration.

Conclusion

In conclusion, STYXL2 is a protein that is highly conserved across various species and has been shown to regulate the microtubule network. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate. The recent studies have identified STYXL2 as a potential drug target for the inhibitor BAY 94-9342 and as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further studies are needed to confirm these findings and to explore the full potential of STYXL2 as a drug target and biomarker.

Protein Name: Serine/threonine/tyrosine Interacting Like 2

Functions: May be required for myofiber maturation

The "STYXL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STYXL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets